Skip to content

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03584217
Acronym
Renal-HEIR
Enrollment
100
Registered
2018-07-12
Start date
2018-10-01
Completion date
2023-10-30
Last updated
2023-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus, Obesity, Nephropathy, Adolescent Obesity

Brief summary

Type 2 diabetes (T2D) in youth is increasing in prevalence in parallel with the obesity epidemic. In the US, almost half of patients with renal failure have DKD, and ≥80% have T2D. Compared to adult-onset T2D, youth with T2D have a more aggressive phenotype with greater insulin resistance (IR), more rapid β-cell decline and higher prevalence of diabetic kidney disease (DKD), arguing for separate and dedicated studies in youth-onset T2D. Hyperfiltration is common in youth with T2D, and predicts progressive DKD. Hyperfiltration may also be associated with early changes in intrarenal hemodynamic function, including increased renal plasma flow (RPF) and glomerular pressure. Despite the high prevalence and gravity of DKD in youth-onset T2D, widely effective therapeutic options are lacking. The investigators' preliminary data support a strong association between IR and hyperfiltration in youth-onset T2D, but the pathology contributing to this relationship remains unclear. A better understanding of the pathophysiology underlying hyperfiltration and its relationship with IR is critical to inform development of new therapeutics. The investigators' overarching hypotheses are that: 1) hyperfiltration in youth-onset T2D is associated with changes in intrarenal hemodynamics, resulting in increased renal oxygen demand, 2) the demand is unmet by the inefficient fuel profile associated with IR (decreased glucose oxidation and increase free fatty acid \[FFA\] oxidation), resulting in renal hypoxia and ultimately renal damage. To address these hypotheses, the investigators will measure peripheral insulin sensitivity, adipose insulin sensitivity (FFA suppression), glomerular filtration rate (GFR), RPF, and renal oxygenation in youth with T2D (n=60), obesity (n=20) and in lean (n=20) controls. To further investigate the mechanisms of renal damage in youth with T2D, two optional procedures are included in the study: 1) kidney biopsy procedure and 2) induction of induced pluripotent stem cells (iPSCs) to assess morphometrics and genetic expression of renal tissue.

Interventions

Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

PROCEDURERenal Biopsy

Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 21 Years
Healthy volunteers
Yes

Inclusion criteria

* Obese youth with and without T2D (≥54 kg) and lean controls * Age 12-21 years * Weight \<300 lbs., no implanted metal devices * HbA1c \< 11% and no recent diabetic ketoacidosis or hyperosmolar hyperglycemia * No anemia * BMI \>5th percentile for lean controls

Exclusion criteria

* T2D onset (diagnosis) \> 18 years of age * Prepubertal * eGFR \<60ml/min/1.73m2 or creatinine \> 1.5mg/dl or history of ACR≥300mg/g * ACE inhibitors, angiotensin receptor blockers (ARB), diuretics, sodium-glucose co-transport (SGLT) 2 or 1 blockers, daily NSAIDs or aspirin, sulfonamides, procaine, thiazosulfone or probenecid. * Seafood or iodine allergy * Pregnancy * MRI scanning contraindications (claustrophobia, implantable devices, \>300 lbs) Additional

Design outcomes

Primary

MeasureTime frameDescription
Effective renal plasma flow (ERPF)4 hoursMeasured by PAH clearance
Glomerular filtration rate (GFR)4 hoursMeasured by iohexol clearance

Secondary

MeasureTime frameDescription
Insulin sensitivity4 hoursMeasured by hyperinsulinemic-euglycemic clamp
Renal oxygenation60 minBlood oxygen level dependent (BOLD) MRI
Renal perfusion10 minArterial spin labeling (ASL) MRI

Other

MeasureTime frameDescription
Number and identity of RNA in kidney cells4 hoursMeasured from tissue obtained by renal biopsy
Podocyte volume of glomeruli4 hoursMeasured by electron microscopy from tissue obtained by renal biopsy
Epigenetic profiling4 hoursMeasured from tissue obtained by renal biopsy
Podocyte numerical density and number per glomerulus4 hoursMeasured by light microscopy from tissue obtained by renal biopsy
Foot process width of glomeruli4 hoursMeasured by electron microscopy from tissue obtained by renal biopsy
Detachment and endothelial fenestration of glomeruli4 hoursMeasured by electron microscopy from tissue obtained by renal biopsy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026